By means of this exclusive licensing-in agreement Almirall will be responsible for the commercialization of linaclotide in all country members of the EU, plus Russia, CIS, Switzerland, Norway
Christine Horton, CEO of CoreSpine Technologies, said: “The clearance of the Xtend-ST device is truly a significant achievement for CoreSpine. The Xtend-ST is a safe and effective device
The planned 46 patients have been enrolled and are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label Phase II study is to assess the
Under the terms of the agreement, Tessella and Cmed will ensure interoperability of Timaeus, the intelligent data acquisition and management system with Tessella Fates, Tessella’s fixed and adaptive
Prior to joining NeuroMetrix, Mr Christensen was the senior vice president of global sales at Stereotaxis. Prior to Stereotaxis, Mr Christensen was vice president for mid America zone
Most recently Dr Peake served as the secretary of veterans affairs and formerly as US army surgeon general. Dr Peake’s military and medical career also includes service as
Dr Lewis-Hall will be the senior physician in the company, responsible for enterprise-wide medical, patient safety, regulatory affairs and quality assurance as well as outreach to doctors and
Mr Tobin, who also will be joining Health Discovery Corporation’s (HDC) board of directors, will be responsible for strategic and operational leadership of HDC. Mr Tobin most recently
Fovea Pharmaceuticals, a French biopharmaceutical company, has reported positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin in patients with persistent allergic conjunctivitis.
Can-Fite BioPharma, an Israeli science-based biopharmaceutical company, has reported top line results from its Phase IIb study in rheumatoid arthritis patients which indicate that the study failed to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.